Drug Trial Radar · NCT02410772
TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens
Last checked: Nov 20, 2026Latest source record: Dec 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,516
Actual
Start
Jan 25, 2016
Primary completion
Jul 2020
Study completion May 2021
Sponsor
- Lead sponsor
- Centers for Disease Control and PreventionFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- First posted
- Apr 8, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a standard six-month regimen for treatment of pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each week, with direct observation of each dose by a health-care worker at least five of the seven days of each week. The standard six-month regimen is two months of isoniazid, rifampin, ethambutol, and pyrazinamide followed by four months of isoniazid and rifampin. The first short regimen is a single substitution of rifapentine for rifampin: two months of isoniazid, rifapentine, ethambutol, and pyrazinamide, followed by two months of isoniazid and rifapentine. The second short regimen is a double substitution of rifapentine for rifampin and moxifloxacin for ethambutol: two months of isoniazid, rifapentine, moxifloxacin, and pyrazinamide, followed by two months of isoniazid, rifapentine, and moxifloxacin. Target enrollment is 2500 participants. Each study participant will remain in the study for 18 months in order to include at least 12 months of evaluation of whether the participant's TB recurs.
Conditions
- Tuberculosis
Interventions
rifapentineDrug
Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment
rifapentine and moxifloxacinDrug
Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.
controlDrug
standard six-month treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3 (2HPZM/2HPM) and Regimen2 (2HPZ/2HP) (Modified Intent to Treat [MITT] Population)Time frame: Twelve months after treatment assignment
- TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3 (2HPZM/2HPM) and Regimen2 (2HPZ/2HP) (Assessable Population)Time frame: Twelve months after treatment assignment
- Percentage Participants With Grade 3 or Higher Adverse Events During Study Drug Treatment in Control Regimen (Regimen 1 2HRZE/4HR) Compared to Experimental Regimens, Regimen 3 (2HPZM/2HPM) and Regimen 2 (2HPZ/2HP) (Safety Analysis Population)Time frame: Four months and up to 14 days after last does of after study treatment (Regimen 2 and 3) or Six months and up to 14 days after last does of after study treatment (Regimen 1)
Locations
33 sites in 13 countries. Site status is shown where the registry gives one.
TBTC Site 82/ ACTG Site 801 USCF AIDS CRS
San Francisco, California
TBTC Site 24 Columbia Unversity
New York, New York
TBTC Site 20 UNTHSC (University of North Texas Health Science Center)
Fort Worth, Texas
TBTC Site 62 Baylor College of Medicine & Affiliated Hospitals/VA
Houston, Texas
TBTC Site 63 San Antonio VA Medical Center (South Texas Group)
San Antonio, Texas
TBTC Site 91/ ACTG Site 12101 Insituto Nacional de Pesquisa Clínica Evandro Chagas
Rio de Janeiro, Brazil
TBTC Site 94/ ACTG Site 12201 Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
TBTC Site 36 TB and Chest Service of Hong Kong, China
Hong Kong, China
TBTC Site 67/ ACTG Site 31730 GHESKIO centers IMIS
Port-au-Prince, Ouest, Haiti
TBTC Site 45/ ACTG Site 30022: Les Centres Gheskio (INLR)
Port-au-Prince, Ouest, Haiti
TBTC Site 43/ ACTG Site 31441 BJ Medical College
Pune, Maharashtra, India
TBTC Site 44/ ACTG Site 11701 CART CRS, YRGCARE Medical Centre VHS
Chennai, Tamil Nadu, India
TBTC Site 03/ ACTG Site 12601 Moi University Clinical Research Site
Eldoret, Kenya
TBTC Site 02/ ACTG 12501 Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS
Kericho, Kericho County, Kenya
TBTC Site 39/ ACTG Site 31460 Kisumu CRS
Kisumu, Nyanza Province, Kenya
TBTC Site 04/ ACTG Site 30301 Blantyre CRS (or College of Medicine - Johns Hopkins Research Project, COM-JHP)
Blantyre, Malawi
TBTC Site 05/ ACTG Site 12001 UNC Project Tidziwe Centre
Lilongwe, Malawi
TBTC Site 90/ ACTG Site 11301 Asociacion Civil Impacta Salud y Educacion
Lima, Peru
TBTC Site 93/ ACTG Site 11302 CRS San Miguel
Lima, Peru
TBTC Site 07/ ACTG Site 11101 Wits Helen Joseph CRS
Johannesburg, South Africa
TBTC Site 10/ ACTG Site 31718 TASK Applied Science
Bellville, Cape Town, South Africa
TBTC Site 09/ ACTG Site 31792 University of Cape Town Lung Institute (Pty) Ltd
Mowbray, Cape Town, South Africa
TBTC Site 34 Wits Health Consortium Perinatal HIV Research Unit (PHRU)
Soweto, Gauteng, South Africa
TBTC Site 49/ ACTG Site 12301 Soweto ACTG CRS
Soweto, Johannesburg, South Africa
TBTC Site 06/ ACTG Site 11201 Durban International Clinical Research Site
Durban, KwaZulu-Natal, South Africa
TBTC Site 01/ACTG Site 8950 FAM CRU
Parow Valley, Western Cape, South Africa
TBTC Site 08/ ACTG Site 31793 South African Tuberculosis Vaccine Initiative (SATVI)
Cape Town, Western Province, South Africa
TBTC Site 42/ ACTG Site 31802 The Thai Red Cross AIDS Research Centre
Pathumwan, Bangkok, Thailand
TBTC Site 69/ ACTG Site 31784 Thai-CTIU, CMU HIV Treatment CRS
Muang Chiang Mai, Chiang Mai, Thailand
TBTC Site 11/ ACTG Site 12401 Joint Clinical Research Centre, Kampala Clinical Research Site
Kampala, Uganda
TBTC Site 30 Uganda-Case Western Reserve Research Collaboration
Kampala, Uganda
TBTC Site 37 Vietnam NTP/UCSF Research Collaboration
Hanoi, Vietnam
TBTC Site 41/ ACTG Site 30313 Parirenyatwa Clinical Research Site
Harare, Zimbabwe
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.